DE202004021680U1 - Feste pharmazeutische Zusammensetzung - Google Patents

Feste pharmazeutische Zusammensetzung Download PDF

Info

Publication number
DE202004021680U1
DE202004021680U1 DE202004021680U DE202004021680U DE202004021680U1 DE 202004021680 U1 DE202004021680 U1 DE 202004021680U1 DE 202004021680 U DE202004021680 U DE 202004021680U DE 202004021680 U DE202004021680 U DE 202004021680U DE 202004021680 U1 DE202004021680 U1 DE 202004021680U1
Authority
DE
Germany
Prior art keywords
composition according
alkyl
oder
receptor agonist
sugar alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE202004021680U
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Tanabe Pharma Corp
Original Assignee
Novartis AG
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE202004021680(U1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG, Mitsubishi Pharma Corp filed Critical Novartis AG
Publication of DE202004021680U1 publication Critical patent/DE202004021680U1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE202004021680U 2003-04-08 2004-04-06 Feste pharmazeutische Zusammensetzung Expired - Lifetime DE202004021680U1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08
US60461215 2003-04-08
DE102004016947A DE102004016947A1 (de) 2003-04-08 2004-04-06 Feste pharmazeutische Zusammensetzung

Publications (1)

Publication Number Publication Date
DE202004021680U1 true DE202004021680U1 (de) 2010-04-22

Family

ID=32326722

Family Applications (4)

Application Number Title Priority Date Filing Date
DE202004021680U Expired - Lifetime DE202004021680U1 (de) 2003-04-08 2004-04-06 Feste pharmazeutische Zusammensetzung
DE201112100047 Pending DE122011100047I1 (de) 2003-04-08 2004-04-06 Feste pharmazeutische darreichungsformen mit einemS1P rezeptoragonisten und einem zuckeralkohol.
DE102004016947A Ceased DE102004016947A1 (de) 2003-04-08 2004-04-06 Feste pharmazeutische Zusammensetzung
DE602004017847T Expired - Lifetime DE602004017847D1 (de) 2003-04-08 2004-04-06 Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol

Family Applications After (3)

Application Number Title Priority Date Filing Date
DE201112100047 Pending DE122011100047I1 (de) 2003-04-08 2004-04-06 Feste pharmazeutische darreichungsformen mit einemS1P rezeptoragonisten und einem zuckeralkohol.
DE102004016947A Ceased DE102004016947A1 (de) 2003-04-08 2004-04-06 Feste pharmazeutische Zusammensetzung
DE602004017847T Expired - Lifetime DE602004017847D1 (de) 2003-04-08 2004-04-06 Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol

Country Status (41)

Country Link
US (11) US20060275357A1 (cg-RX-API-DMAC7.html)
EP (5) EP1613288B1 (cg-RX-API-DMAC7.html)
JP (3) JP5495467B2 (cg-RX-API-DMAC7.html)
KR (3) KR20110005320A (cg-RX-API-DMAC7.html)
CN (2) CN1767819B (cg-RX-API-DMAC7.html)
AR (3) AR043987A1 (cg-RX-API-DMAC7.html)
AT (3) ATE414508T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004228929B2 (cg-RX-API-DMAC7.html)
BE (2) BE1015972A5 (cg-RX-API-DMAC7.html)
BR (1) BRPI0409250B8 (cg-RX-API-DMAC7.html)
CA (2) CA2707750A1 (cg-RX-API-DMAC7.html)
CL (2) CL2004000745A1 (cg-RX-API-DMAC7.html)
CY (3) CY1110260T1 (cg-RX-API-DMAC7.html)
DE (4) DE202004021680U1 (cg-RX-API-DMAC7.html)
DK (2) DK2316431T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP056090A (cg-RX-API-DMAC7.html)
ES (3) ES2556947T3 (cg-RX-API-DMAC7.html)
FR (2) FR2854073B1 (cg-RX-API-DMAC7.html)
GB (1) GB2400318B (cg-RX-API-DMAC7.html)
GR (1) GR1005052B (cg-RX-API-DMAC7.html)
HR (3) HRP20100601B1 (cg-RX-API-DMAC7.html)
HU (2) HUE028247T2 (cg-RX-API-DMAC7.html)
IL (3) IL170888A (cg-RX-API-DMAC7.html)
IS (2) IS2682B (cg-RX-API-DMAC7.html)
IT (1) ITMI20040682A1 (cg-RX-API-DMAC7.html)
LU (1) LU91867I2 (cg-RX-API-DMAC7.html)
MA (1) MA27729A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05010860A (cg-RX-API-DMAC7.html)
MY (1) MY141249A (cg-RX-API-DMAC7.html)
NO (4) NO329332B1 (cg-RX-API-DMAC7.html)
NZ (3) NZ586280A (cg-RX-API-DMAC7.html)
PE (5) PE20131352A1 (cg-RX-API-DMAC7.html)
PL (2) PL2316431T3 (cg-RX-API-DMAC7.html)
PT (1) PT1613288E (cg-RX-API-DMAC7.html)
RU (5) RU2358716C2 (cg-RX-API-DMAC7.html)
SG (1) SG175449A1 (cg-RX-API-DMAC7.html)
SI (2) SI2316431T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN05256A1 (cg-RX-API-DMAC7.html)
TW (1) TWI332847B (cg-RX-API-DMAC7.html)
WO (1) WO2004089341A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200507394B (cg-RX-API-DMAC7.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1773307T3 (pl) * 2004-07-30 2015-03-31 Novartis Ag Preparaty 2-amino-1,3-propanodioli i ich analogów
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
NZ566137A (en) * 2005-09-09 2011-05-27 Novartis Ag The use of diphenyl thioether derivatives to treat autoimmune diseases
EP2623113B1 (en) 2005-11-09 2017-05-31 Onyx Therapeutics, Inc. Compound for enzyme inhibition
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
RU2487703C2 (ru) * 2006-09-26 2013-07-20 Новартис Аг Фармацевтические композиции, включающие модулятор s1р
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
FI2140867T4 (fi) 2007-03-29 2023-09-14 Farmaseuttinen koostumus
CA2701778C (en) 2007-10-04 2018-09-11 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
WO2009048993A2 (en) * 2007-10-12 2009-04-16 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
JP5452237B2 (ja) 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
CA2716448A1 (en) 2008-03-17 2009-09-24 Patrick Brossard Dosing regimen for a selective s1p1 receptor agonist
WO2009155475A1 (en) 2008-06-20 2009-12-23 Novartis Ag Paediatric compositions for treating1 multiple sclerosis
EP2299982B1 (de) * 2008-06-20 2018-04-04 Merck Patent GmbH Direkt verpressbare und schnell zerfallende tablettenmatirx
ES2377869T3 (es) * 2008-09-04 2012-04-02 Cargill, Incorporated Fabricación de comprimidos de eritritol
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
JP2012508215A (ja) 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
CN104788325A (zh) * 2008-11-11 2015-07-22 诺华股份有限公司 芬戈莫德的结晶形式
AU2013100531B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
MY150973A (en) 2008-12-17 2014-03-31 Daiichi Sankyo Co Ltd Method for producing diamine derivative
WO2010082531A1 (ja) 2009-01-13 2010-07-22 第一三共株式会社 活性化血液凝固因子阻害剤
WO2010104078A1 (ja) 2009-03-10 2010-09-16 第一三共株式会社 ジアミン誘導体の製造方法
CN102348680B (zh) 2009-03-13 2014-11-05 第一三共株式会社 用于制备光学活性二胺衍生物的方法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
BRPI1011804A2 (pt) * 2009-06-18 2018-02-27 Daiichi Sankyo Company, Limited composição farmacêutica com solubilidade melhorada
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
WO2011115066A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
BR112012023654B1 (pt) 2010-03-19 2022-04-12 Daiichi Sankyo Company, Limited Método para produzir grânulos contendo agente anticoagulante e método para produzir uma composição farmacêutica contendo o dito agente
CA2797029A1 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh A method of preparing an oral dosage form comprising fingolimod
CA2859191C (en) 2010-07-02 2016-05-17 Daiichi Sankyo Company, Limited Process for preparation of optically active diamine derivative salt
WO2012070059A1 (en) 2010-11-25 2012-05-31 Shilpa Medicare Limited Fingolimod polymorphs and their processes
SG191286A1 (en) 2011-01-07 2013-07-31 Novartis Ag Immunosuppressant formulations
DK2665471T3 (en) 2011-01-19 2018-03-19 Pathologica Llc ORAL PHARMACEUTICAL DOSAGE FORMS WITH MANAGED RELEASE COMPREHENSIVE MGBG
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
WO2013019872A1 (en) 2011-08-01 2013-02-07 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
EP2742941B1 (en) 2011-08-10 2018-04-18 Daiichi Sankyo Company, Limited Pharmaceutical composition containing diamine derivative
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
CN105163730B (zh) * 2013-01-08 2018-10-30 帕萨罗杰卡有限公司 用于治疗脱髓鞘疾病的方法和组合物
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
JP6294872B2 (ja) * 2013-04-26 2018-03-14 国立大学法人京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
MX370184B (es) * 2013-05-13 2019-12-04 Synthon Bv Composición farmacéutica que comprende fingolimod.
EP3027174B1 (en) 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
US20170231928A1 (en) * 2014-08-22 2017-08-17 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
WO2016118515A1 (en) 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
WO2022015348A1 (en) 2020-07-16 2022-01-20 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection
EP4438037A1 (en) * 2021-01-28 2024-10-02 Priothera SAS Methods of treatment with s1p receptor modulators
AU2021424131B2 (en) * 2021-01-28 2026-08-13 Priothera Limited Methods of treatment with s1p receptor modulators

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627406A1 (en) 1992-10-21 1994-12-07 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
EP0778263A1 (en) 1994-08-22 1997-06-11 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and medicinal use thereof
WO1997024112A1 (en) 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. External preparation
US6004565A (en) 1997-09-02 1999-12-21 Yoshitomi Pharmaceutical Industries, Ltd. Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties
EP1002792A1 (en) 1997-04-04 2000-05-24 Yoshitomi Pharmaceutical Industries, Ltd. 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
WO2001001978A1 (fr) 1999-06-30 2001-01-11 Mitsubishi Pharma Corporation Compositions de medicaments servant a prevenir ou a traiter la myocardite virale
US6274629B1 (en) 1996-11-19 2001-08-14 Novartis Ag Use for 1,3-propanediol derivatives
WO2002006268A1 (en) 2000-07-13 2002-01-24 Sankyo Company, Limited Amino alcohol derivatives
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
WO2002076995A2 (en) 2001-03-26 2002-10-03 Novartis Ag 2-amino-propanol derivatives
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
WO2003029184A1 (en) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
WO2003029205A1 (fr) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Derive de sulfure de diaryle, son sel d'addition et immunosuppresseur
WO2003062248A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
WO2003062252A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
WO2003061567A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
EP2030614A1 (en) * 1997-02-27 2009-03-04 Novartis AG Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
EP1195165A4 (en) * 1999-07-12 2005-08-10 Ono Pharmaceutical Co FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JPWO2003020313A1 (ja) 2001-09-04 2004-12-16 小野薬品工業株式会社 スフィンゴシン−１−リン酸受容体調節剤からなる呼吸器疾患治療剤
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
CN101905023B (zh) * 2004-07-16 2012-07-11 杏林制药株式会社 有效的医药使用方法及与副作用发生的防御相关的方法

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627406A1 (en) 1992-10-21 1994-12-07 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
US5604229A (en) 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
EP0778263A1 (en) 1994-08-22 1997-06-11 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and medicinal use thereof
WO1997024112A1 (en) 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. External preparation
US6274629B1 (en) 1996-11-19 2001-08-14 Novartis Ag Use for 1,3-propanediol derivatives
EP1002792A1 (en) 1997-04-04 2000-05-24 Yoshitomi Pharmaceutical Industries, Ltd. 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
US6004565A (en) 1997-09-02 1999-12-21 Yoshitomi Pharmaceutical Industries, Ltd. Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties
WO2001001978A1 (fr) 1999-06-30 2001-01-11 Mitsubishi Pharma Corporation Compositions de medicaments servant a prevenir ou a traiter la myocardite virale
WO2002006268A1 (en) 2000-07-13 2002-01-24 Sankyo Company, Limited Amino alcohol derivatives
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
WO2002076995A2 (en) 2001-03-26 2002-10-03 Novartis Ag 2-amino-propanol derivatives
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
WO2003029184A1 (en) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
WO2003029205A1 (fr) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Derive de sulfure de diaryle, son sel d'addition et immunosuppresseur
WO2003062248A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
WO2003062252A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
WO2003061567A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DS. Im et al., Mol. Pharmacol. 2000, 57, 753
H. Sucker et al., Pharmazeutische Technologie, Thieme, 1991
L. Lachman et al., The Theory and Practice of Industrial Pharmacy, 3. Ausgabe, 1986
M. Wigler et al., Cell, 1977, 11, 223
Nagers Handbuch der pharmazeutischen Praxis, 4. Ausgabe (Springer Verlag, 1971)
Remington's Pharmaceutical Sciences, 13. Ausgabe, (Mack Publ., Co., 1970)

Also Published As

Publication number Publication date
GR20040100121A (el) 2004-12-17
US20220031609A1 (en) 2022-02-03
JP2004307506A (ja) 2004-11-04
US20110105620A1 (en) 2011-05-05
JP2011006461A (ja) 2011-01-13
NO334116B1 (no) 2013-12-16
AR078782A2 (es) 2011-11-30
ZA200507394B (en) 2007-03-28
HRP20050886A2 (en) 2006-11-30
NO335120B1 (no) 2014-09-22
FR11C0036I2 (fr) 2023-12-29
MA27729A1 (fr) 2006-01-02
ECSP056090A (es) 2006-03-01
CY1110260T1 (el) 2014-04-09
US20140011885A1 (en) 2014-01-09
HK1155647A1 (en) 2012-05-25
US20090203798A1 (en) 2009-08-13
TWI332847B (en) 2010-11-11
EP2008650A3 (en) 2011-04-27
GR1005052B (el) 2005-11-30
FR11C0036I1 (fr) 2011-10-14
JP5495467B2 (ja) 2014-05-21
WO2004089341A1 (en) 2004-10-21
CA2521325A1 (en) 2004-10-21
IE20040246A1 (en) 2004-12-15
AT501681B1 (de) 2012-04-15
RU2012148593A (ru) 2014-05-20
EP2319502A1 (en) 2011-05-11
DE102004016947A1 (de) 2004-10-21
RU2005134173A (ru) 2006-09-10
AT504853A2 (de) 2008-08-15
PE20150676A1 (es) 2015-05-17
AR078781A2 (es) 2011-11-30
CA2521325C (en) 2010-09-14
LU91867I2 (fr) 2011-11-08
NO20131287L (no) 2006-01-09
CN101797241A (zh) 2010-08-11
GB0407819D0 (en) 2004-05-12
CY2011013I2 (el) 2014-04-09
IS8885A (is) 2010-02-25
HRP20050886B1 (en) 2011-01-31
US20060275357A1 (en) 2006-12-07
US20200237690A1 (en) 2020-07-30
RU2010146697A (ru) 2012-05-27
BRPI0409250B1 (pt) 2017-07-11
ES2556947T3 (es) 2016-01-21
IS2682B (is) 2010-10-15
HUS1100016I1 (hu) 2016-08-29
TNSN05256A1 (en) 2007-07-10
US20140255497A1 (en) 2014-09-11
CA2707750A1 (en) 2004-10-21
AR043987A1 (es) 2005-08-17
US8324283B2 (en) 2012-12-04
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
FR2854073B1 (fr) 2008-03-14
PE20050396A1 (es) 2005-07-05
NZ592339A (en) 2012-09-28
CY1117071T1 (el) 2017-04-05
CN1767819A (zh) 2006-05-03
TW200503784A (en) 2005-02-01
PL1613288T3 (pl) 2009-07-31
BRPI0409250A (pt) 2006-03-28
KR20120101148A (ko) 2012-09-12
AU2004228929B2 (en) 2008-02-07
PE20131352A1 (es) 2013-11-14
NZ542622A (en) 2009-01-31
NO20055231D0 (no) 2005-11-07
DE602004017847D1 (de) 2009-01-02
US20190175527A1 (en) 2019-06-13
JP2013177404A (ja) 2013-09-09
EP2769713A1 (en) 2014-08-27
DK1613288T3 (da) 2009-03-23
RU2010147000A (ru) 2012-08-10
IL197578A0 (en) 2011-07-31
SI2316431T1 (sl) 2016-04-29
ATE414508T1 (de) 2008-12-15
EP2316431B1 (en) 2015-09-30
HUE028247T2 (en) 2016-12-28
EP1613288A1 (en) 2006-01-11
US20080311188A1 (en) 2008-12-18
CN101797241B (zh) 2013-03-27
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
RU2475236C2 (ru) 2013-02-20
IL170888A (en) 2010-06-16
KR101367574B1 (ko) 2014-02-25
EP2008650A2 (en) 2008-12-31
JP5543298B2 (ja) 2014-07-09
HK1091114A1 (en) 2007-01-12
ES2228282A1 (es) 2005-04-01
US20170290787A1 (en) 2017-10-12
CY2011013I1 (el) 2014-04-09
GB2400318B (en) 2005-08-10
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
HRP20100601A2 (hr) 2011-03-31
HRP20100600A2 (hr) 2011-03-31
ES2320767T3 (es) 2009-05-28
ES2228282B1 (es) 2006-02-16
KR20110005320A (ko) 2011-01-17
NO2011016I1 (no) 2011-09-19
EP1613288B1 (en) 2008-11-19
RU2358716C2 (ru) 2009-06-20
CN1767819B (zh) 2010-07-28
PE20090743A1 (es) 2009-07-17
SG175449A1 (en) 2011-11-28
FR2854073A1 (fr) 2004-10-29
DE122011100047I1 (de) 2011-12-15
US20130108675A1 (en) 2013-05-02
NZ586280A (en) 2011-12-22
BE2011C030I2 (cg-RX-API-DMAC7.html) 2023-03-07
DK2316431T3 (en) 2016-01-11
BRPI0409250B8 (pt) 2022-01-18
IS8114A (is) 2005-11-01
LU91867I9 (cg-RX-API-DMAC7.html) 2019-01-03
SI1613288T1 (sl) 2009-04-30
NO20100250L (no) 2006-01-09
CL2004000745A1 (es) 2005-02-11
MY141249A (en) 2010-03-31
MXPA05010860A (es) 2006-05-25
AT501681A1 (de) 2006-10-15
RU2475237C2 (ru) 2013-02-20
NO329332B1 (no) 2010-09-27
RU2009105403A (ru) 2010-08-27
PT1613288E (pt) 2009-02-25
IL242037A0 (en) 2015-11-30
KR20050121712A (ko) 2005-12-27
ITMI20040682A1 (it) 2004-07-06
IL197578A (en) 2015-10-29
NO2011016I2 (no) 2012-08-27
PE20130200A1 (es) 2013-03-09
GB2400318A (en) 2004-10-13
AU2004228929A1 (en) 2004-10-21
HRP20100601B1 (hr) 2016-12-02

Similar Documents

Publication Publication Date Title
DE102004016947A1 (de) Feste pharmazeutische Zusammensetzung
DE69629797T2 (de) Matrix zur gesteuerten freisetzung von arzneistoffen
KR20080035608A (ko) 액상 제제
HK1091114B (en) Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
HK1155650A (en) Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
HK1155647B (en) Solid oral composition comprising a s1p receptor agonist and a sugar alcohol

Legal Events

Date Code Title Description
R207 Utility model specification

Effective date: 20100527

R151 Utility model maintained after payment of second maintenance fee after six years

Effective date: 20100526

R152 Utility model maintained after payment of third maintenance fee after eight years

Effective date: 20120502

R082 Change of representative

Representative=s name: DR. SCHOEN & PARTNER, DE

R081 Change of applicant/patentee

Owner name: NOVARTIS AG, CH

Free format text: FORMER OWNER: NOVARTIS AG, MITSUBISHI PHARMA CORP., , JP

Effective date: 20130719

Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JP

Free format text: FORMER OWNER: NOVARTIS AG, MITSUBISHI PHARMA CORP., , JP

Effective date: 20130719

Owner name: MITSUBISHI TANABE PHARMA CORPORATION, 541-8505, JP

Free format text: FORMER OWNER: NOVARTIS AG, MITSUBISHI PHARMA CORP., , JP

Effective date: 20130719

Owner name: NOVARTIS AG, CH

Free format text: FORMER OWNERS: NOVARTIS AG, BASEL, CH; MITSUBISHI PHARMA CORP., OSAKA, JP

Effective date: 20130719

Owner name: MITSUBISHI TANABE PHARMA CORPORATION, 541-8505, JP

Free format text: FORMER OWNERS: NOVARTIS AG, BASEL, CH; MITSUBISHI PHARMA CORP., OSAKA, JP

Effective date: 20130719

Owner name: MITSUBISHI TANABE PHARMA CORPORATION, 541-8505, JP

Free format text: FORMER OWNERS: NOVARTIS AG, 4056 BASEL, CH; MITSUBISHI PHARMA CORP., OSAKA, JP

Effective date: 20130719

Owner name: NOVARTIS AG, CH

Free format text: FORMER OWNERS: NOVARTIS AG, 4056 BASEL, CH; MITSUBISHI PHARMA CORP., OSAKA, JP

Effective date: 20130719

R082 Change of representative

Representative=s name: DR. SCHOEN & PARTNER, DE

Effective date: 20130719

Representative=s name: HENKEL, BREUER & PARTNER, DE

Effective date: 20130719

R082 Change of representative

Representative=s name: HENKEL, BREUER & PARTNER, DE

R071 Expiry of right
R071 Expiry of right